Cancer Related Anemia
Dr. David Henry talks about the undertreatment of patients with cancer-related anemia.
Video originally published on PracticeUpdate on 10/29/2018 - https://www.practiceupdate.com/c/69057/48/1.
--
Follow PracticeUpdate:
Twitter: https://twitter.com/practiceupdate
Facebook: https://www.facebook.com/practiceupdate
Instagram: https://www.instagram.com/practiceupdate_elsevier
LinkedIn: https://www.linkedin.com/showcase/practiceupdate
Видео Cancer Related Anemia канала PracticeUpdate
Video originally published on PracticeUpdate on 10/29/2018 - https://www.practiceupdate.com/c/69057/48/1.
--
Follow PracticeUpdate:
Twitter: https://twitter.com/practiceupdate
Facebook: https://www.facebook.com/practiceupdate
Instagram: https://www.instagram.com/practiceupdate_elsevier
LinkedIn: https://www.linkedin.com/showcase/practiceupdate
Видео Cancer Related Anemia канала PracticeUpdate
Показать
Комментарии отсутствуют
Информация о видео
Другие видео канала
The Immune Landscape of Residual TNBC After Neoadjuvant Chemotherapy
Heroin/Opioid Addiction Among Cancer Patients – Recommendations for Patients
A Review of Immunotherapy and Targeted Therapy in Glioblastoma
New Concepts in Metastatic Prostate Cancer
Salvage vs Adjuvant Therapy in High-Risk Prostate Cancer
Erlotinib Plus Ramucirumab for EGFR Mutant Lung Cancer
Practice Implications of Real World Data on First-Line Pazopanib in mRCC
Metastatic Breast Cancer: Triple Negative
PCI versus medical therapy for patients with symptomatic coronary artery disease?
Interview on Multiple Myeloma Trials
Gene Therapy for Advanced Parkinson’s Disease
New Data on Pancreatic Cancer from ASCO GI
Schizophrenia: Acute vs Chronic Management
Adjuvant T-DM1 for Stage I HER2+ Breast Cancer
Depression Management: First-Line Treatments
JAK2 and PD-L1 in 9p24 Amplified Breast Cancer
ADA 2018: Observations from the DEVOTE trial
Immunotherapy in the Management of Metastatic Triple Negative Breast Cancer
Mitoxantrone and Veliparib in Prostate Cancer: Updates from ASCO 2017
Use of Colony-Stimulating Factors Among Patients Receiving Intermediate-Risk Chemotherapies